LNP023
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Nocturnal Hemoglobinuria
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Trial Timeline
Jun 10, 2025 → Apr 20, 2027
NCT ID
NCT06931691About LNP023
LNP023 is a pre-clinical stage product being developed by Novartis for Paroxysmal Nocturnal Hemoglobinuria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06931691. Target conditions include Paroxysmal Nocturnal Hemoglobinuria.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06934967 | Phase 3 | Recruiting |
| NCT06931691 | Pre-clinical | Recruiting |
| NCT04557462 | Phase 3 | Recruiting |
| NCT03955445 | Phase 3 | Recruiting |
| NCT03896152 | Phase 2 | Completed |
| NCT03832114 | Phase 2 | Completed |
| NCT03373461 | Phase 2 | Completed |
Competing Products
20 competing products in Paroxysmal Nocturnal Hemoglobinuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 41 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Danicopan | AstraZeneca | Phase 3 | 77 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 77 |
| iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Pre-clinical | 23 |
| Iptacopan | Novartis | Phase 3 | 77 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 3 | 77 |
| LFG316 + LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Crovalimab | Roche | Phase 3 | 77 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 76 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 51 |
| Humanized anti-Factor Bb monoclonal antibody + Placebo | Sanofi | Phase 1 | 32 |